# Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment

> **NCT01425294** · — · TERMINATED · sponsor: **AstraZeneca** · enrollment: 231 (actual)

## Conditions studied

- Breast Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01425294
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2011-08-01
- **Primary completion:** 2016-01-30
- **Final completion:** 2016-01-30
- **Target enrollment:** 231 (ACTUAL)
- **Why stopped:** The study has been decided to be early terminated for the FAS 500 mg has launched in 2015. The use mothod of 250mg per month in clinical practice is off-label.
- **Last updated:** 2017-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01425294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01425294, "Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01425294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*